@priya The study met its primary endpoint of percentage of patients with HBV DNA levels < 20 IU/mL at 24 weeks of therapy, Gilead said in a press release.
Overall, 10 of 47 (21%) patients treated with tenofovir alafenamide achieved HBV DNA < 20 IU/mL at 24 weeks compared with none of 23 (0%) treated with placebo.
The rates of serum alanine aminotransferase normalization were higher with tenofovir alafenamide than with placebo (44% vs 0%).
The mean percent changes in bone mineral density (BMD) from baseline to 24 weeks were numerically similar for tenofovir alafenamide- and placebo-treated patients (2.4% and 1.9% for lumbar spine, and 1.5% and 1.9% for whole body, respectively).